Elvin L. Johnson
Papers
2
Total Citations
9
H-Index
2
About
Elvin L. Johnson is a pioneering figure in the field of bioanalytical chemistry, with a specialized focus on the development of sensitive and robust chromatographic methods for quantifying novel therapeutic compounds in biological matrices. His work is foundational for the pharmacokinetic profiling of central nervous system (CNS) agents, particularly those targeting neuropeptide receptors. Johnson’s most notable contribution is the development and validation of a high-performance liquid chromatographic (HPLC) assay for CI-988, a non-peptide cholecystokinin subtype B (CCK-B) receptor antagonist. This method, published in 1995, enabled precise quantification of the drug in human and monkey plasma, a critical step for advancing research into anxiety and pain modulation. The assay’s sensitivity and specificity, achieved through robotic sample preparation, set a new standard for bioanalysis of CCK antagonists. Earlier in his career, Johnson demonstrated similar ingenuity with a robotic analysis for a furoindole carboxamide compound (1986), showcasing his early adoption of automation to enhance throughput and reproducibility. Though his citation counts (6 and 3, respectively) reflect a niche but highly specialized impact, his work remains a technical benchmark for researchers developing assays for low-concentration, structurally complex drugs. Johnson’s legacy lies in bridging analytical chemistry and neuroscience, providing the tools necessary to translate promising drug candidates from bench to bedside.
Research Focus
Key Achievements
Top Papers
- 1
- 2